GlaxoSmithKline’s Québec City plant, which produces all of Canada’s flu vaccine, will benefit from a $90 million modernization. The project involves replacing the sterile filling and packaging line with a new larger-capacity line, which is scheduled for completion in 2012. The investment will enable GSK to boost its pandemic vaccine production capacity and to reduce delivery times in the event that the World Health Organization declares another pandemic.
The Government of Québec will make a non-refundable financial contribution up to a maximum of $20 million over three years, administered by Investissement Québec. The Government of Canada is also a partner in the project.
“We are proud to support the modernization of Canada’s sole flu vaccine manufacturing plant. Québec’s economic development relies on dynamic and prosperous high-tech sectors such as the biopharmaceutical industry, which accounts for more than 145 companies and 20,900 direct jobs. GSK understands that Québec is a place of choice for such investments. With this project, the company is staking its long-term development on Québec,” said Clément Gignac, Minister of Economic Development, Innovation and Export Trade.
“By supporting the development of this world-class company, we are also enhancing our supply self-sufficiency, particularly in terms of flu vaccines, on which GSK is already a key partner,” said Yves Bolduc, Minister of Health and Social Services.
GlaxoSmithKline is the largest employer in the biopharmaceutical sector in Québec (1,300 employees) and across Canada (3,000 employees).
Québec’s biopharmaceutical sector – Ministère du Développement économique, de l'Innovation et de l'Exportation (MDEIE)
Québec’s life sciences sector – Investissement Québec